BioMarin to Acquire Alesta Therapeutics for Hypophosphatasia Program
BioMarin (BMRN) announces an acquisition of Alesta Therapeutics to gain ALE1, described as a potential first oral therapy for hypophosphatasia, adding a clinical program to its pipeline.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.